updated 12/16/2010 7:16:12 AM ET 2010-12-16T12:16:12

DALLAS, Dec. 16, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Somaxon Pharmaceuticals Inc. (Nasdaq:SOMX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/SOMX

Somaxon Pharmaceuticals (SOMX) is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. SOMX's lead product, Silenor, has been approved for the treatment of insomnia characterized by difficulty with sleep maintenance.

Message Board Search for SOMX: http://www.boardcentral.com/boards/SOMX

In the report, the analyst notes:

"SOMX president and CEO Richard W. Pascoe rang the ceremonial NASDAQ stock market opening bell last December 3. The Company celebrated the introduction of Silenor, which it launched in September 2010 with its co-promotion partner Procter & Gamble. This month also marks SOMX's five-year listing on NASDAQ."

"SOMX's MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below 0, which suggests that the underlying moving averages are bearish."

To read the entire report visit: www.microstockprofit.com/lp/SOMX

See what investors are saying about SOMX at http://www.stockhideout.com

Get breaking news on SOMX at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com .

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT:  MicroStockProfit.com
          Brian Johnson
          1-888-307-2850
          info@microstockprofit.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 2.44%
$30K home equity loan FICO 5.78%
$75K home equity loan FICO 4.54%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.57%
13.57%
Cash Back Cards 17.91%
17.91%
Rewards Cards 17.15%
17.15%
Source: Bankrate.com